| Objective:Idiopathic interstitial pneumonia(IIP),is a set of unexplained diffuse disease,pathological changes more abuse and pulmonary interstitial,main pathological changes in pulmonary fibrosis.Under the 2012 ATS/ERS of idiopathic interstitial pneumonia classification,divided into primary idiopathic pulmonary interstitial pneumonia,namely fibrosis caused by chronic interstitial pneumonia,such as idiopathic pulmonary fibrosis(IPF)and nonspecific interstitial pneumonia.Acute/subacute interstitial pneumonia,such as hidden source sex machine pneumonia;Smoking related interstitial pneumonia,such as desquamative interstitial pneumonia.Followed by uncommon interstitial pneumonia,mainly are idiopathic lymphocytic interstitial pneumonia.End for not classification of IIP,autoimmune features of interstitial pneumonia(IPAF)fall under this category.In recent years,the incidence of IIP rise year by year,the disease is often caused by a variety of causes,its incidence and case fatality rate increased quickly,which cause serious damage to human health.At present the pathogenesis of IIP is not yet clear,and there is no effective treatment.Pirfenidone is the first drug in the word for IPF indications,has anti fibrosis,anti-inflammatory and antioxidant effect,especially for pulmonary fibrosis.In addition,in the aspect of laboratory examination,there are a variety of serum biomarkers associated with IIP.Research shows that KL-6 in numerous serological markers,there is a higher value in evaluating the degree of disease and prognosis,and KL-6levels of change and the clinical curative effect is relatively consistent,therefore,KL-6 in numerous laboratory indexes,especially notable.The experiment,it was by contrast the lever of KL-6 before and after 3 months with oraling Pirfenidone,in order to assess the influence of the Pirfenidone to KL-6 levels in the serum of IPF and IPAF patients,at the same time,with theapplication of IPAF in IPF patients compared with pirfenidone treatment after3 months whether there is any change in the level of KL-6.Methods:The study collected from January 2016 to January 2017 in Hebei Medical University Hospital east campus after definite diagnosis for a total of 30 patients with IIP(of which 15 patients with idiopathic pulmonary interstitial fibers,for IPF group,autoimmune features of 15 cases,interstitial pneumonia group for IPAF group),were given overlooks the methadone treatment,according to the principle of gradually increasing dosage.1 Statistics of 30 patients' s KL-6 levers into the group of patients,less than 500 as the normal reference range,the number of patients with statistical KL-6 lever greater than 500 of the percentage of patients2 Test the lever of KL-6 in 30 patient named with IIP before and after treatment,will be detected before treatment for group A,the serum levels of KL-6 for group B after treatment,compared the lever of KL-6 in A group with B group,study on the effects of pirfenidone on patients with IIP KL-6level3 Respectively compared the lever of KL-6 before and after treatment for3 months in IPF group and IPAF group,study on the effects of pirfenidone on IPF and IPAF patients with the lever of KL-6.4 Record the IPF group and IPAF group before and after treatment in patients with KL-6 levels in peripheral blood serum,study of IPF group and IPAF KL-6 levels after treatment in patients with whether there is a difference.Resuits:1 In the group of IIP,there was 30 patients,16 cases of men,14 cases is women,the average age was(66.63±5.97)years old.Before treatment,96% of patients with KL-6 levels of more than 500.After 3 months of treatment,the average KL-6 level of(1323.67±719.80)was significantly lower than that before treatment,there was significant difference between the two groups(P <0.05).2 In the group of IPF,7 patients were male,female 8 cases,mean age(68.47±6.98).Before treatment,the average level of KL-6 was(1203.93±685.94),After 3 months of treatment,the average KL-6 level of(1015.87±616.04)was significantly lower than that before treatment,there was significant difference between the two groups(P < 0.05).IPAF group,9 cases of male and female 6 cases,mean age(64.80±4.23),Before treatment,the average level of KL-6 was(1443.40±756.30),After 3months of treatment,the average KL-6 level of(1181.40±719.26)was significantly lower than that before treatment,there was significant difference between the two groups(P < 0.05).3 IPF group,7 patients were male,female 8 cases,mean age(68.47±6.98),IPAF group,9 cases of male,female 6 cases,mean age(64.80±4.23),two groups of patients respectively applied Pirfenidone for 3months,patients with IPF group the average level of KL-6 was(1015.87±616.04),IPAF group was(1181.40±719.26).After statistical analysis,there was no significant difference in age and gender between the two group.After treatment,there was no significant difference in the level of KL-6between the two group.Conclusions:The experimental results showed that KL-6 levels were significantly decreased idiopathic interstitial pneumonia patients with pirfenidone after treatment,with statistical significance,suggesting that idiopathic interstitial pneumonia patients with pirfenidon can improve the prognosis,reduce the disease activity,delaying disease progression.But in idiopathic pulmonary fibrosis group and intersititial pneumonia with autoimmune features were given no obvious differences of pirfenidone treatment,that no significant differences in the clinical efficacy. |
PDF Full Text Request